Antiangiogenic peptides

Details Antiangiogenic peptides Antiangiogenic peptides

2005-08-11

2010-02-02

Landsman, Robert (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S014800, C514S04400A, C514S327000, C530S324000, C530S326000

Reexamination Certificate

active

07655626

ABSTRACT:
The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino acid residue compatible with forming a helix; X2 is an amino acid residue of: Leu, Ile, Val; X3 is an amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an amino acid residue of: Ile, Leu, Val; X5 is any amino acid residue compatible with forming a helix; X6 is an amino acid residue of: Leu, Ile, Val; X7 is an amino acid residue of: Leu, Ile, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: Trp, Tyr, Phe; X13 is an amino acid residue of: Leu, Ile, Val, Asn, Gln; X14 is an amino acid residue of: Glu, Gln, Asp, Asn.

REFERENCES:
patent: 1 378 515 (2004-01-01), None
patent: WO 98/51323 (1998-11-01), None
patent: WO 2006/018418 (2006-02-01), None
Brasseur et al., 1997, TIBS, vol. 22, pp. 167-171.
Nguyen et al., 2006, PNAS, vol. 103, No. 39, pp. 14319-14324.
Kinet et al., “Characterization of Lactogen Receptor-binding Site 1 of Human Prolactin”The Journal of Biological Chemistry271(24): 14353-14360 (1996).
Bushell, G. et al. (1993) “Evidence supporting a role for cathepsin B in the generation of T cell antigenic epitopes of human growth hormone”Molecular Immunology30: 587-591.
Dings, R.P.M. et al. (2003) “Discovery and development of anti-angiogenic peptides: a structural link”Angiogenesis6:83-91.
Lins, L. et al (2001) “Computational study of lipid-destabilizing protein fragments: towards a comprehensive view of tilted peptides”Structure, Function and Genetics44:435-447.
Piossek, C. et al. (1999) “Vascular endothelial growth factor (VEGF) receptor II-derived peptides Inhibit VEGF”The Journal of Biological Chemistry274:5612-5619.

Affiliated with

Also associated with

Rating

Antiangiogenic peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antiangiogenic peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiangiogenic peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4162003